These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14612675)

  • 1. Can we genetically engineer safer and more effective immunotherapy reagents?
    Westritschnig K; Valenta R
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):495-500. PubMed ID: 14612675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant allergens for immunotherapy: state of the art.
    Zhernov Y; Curin M; Khaitov M; Karaulov A; Valenta R
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):402-414. PubMed ID: 31082821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
    Linhart B; Valenta R
    Vaccine; 2012 Jun; 30(29):4328-35. PubMed ID: 22100888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.
    Asturias JA
    Front Biosci (Landmark Ed); 2009 Jan; 14(12):4606-17. PubMed ID: 19273375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
    Valenta R; Campana R; Focke-Tejkl M; Niederberger V
    J Allergy Clin Immunol; 2016 Feb; 137(2):351-7. PubMed ID: 26853127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of hypoallergens applied to the major cat allergen Fel d 1.
    Saarne T; Kaiser L; Grönlund H; Rasool O; Gafvelin G; van Hage-Hamsten M
    Clin Exp Allergy; 2005 May; 35(5):657-63. PubMed ID: 15898990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically modified allergens.
    Niederberger V; Valenta R
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):727-38. PubMed ID: 15474868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant allergens for immunotherapy. Where do we stand?
    Niederberger V; Valenta R
    Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):549-54. PubMed ID: 15640698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New concepts in therapy of type I allergic diseases].
    Valenta R; Steinberger P; Vrtala S; Grote M; Laffer S; Sperr WR; Valent P; Kraft D; Scheiner O
    Wien Klin Wochenschr; 1993; 105(23):682-6. PubMed ID: 7508663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant allergens for pollen immunotherapy.
    Wallner M; Pichler U; Ferreira F
    Immunotherapy; 2013 Dec; 5(12):1323-38. PubMed ID: 24283843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From allergen genes to new forms of allergy diagnosis and treatment.
    Vrtala S
    Allergy; 2008 Mar; 63(3):299-309. PubMed ID: 18269675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Bugajska-Schretter ; Ball T; Twardosz A; Spitzauer S; Grönlund H; Kraft D
    Biol Chem; 1999; 380(7-8):815-24. PubMed ID: 10494830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular allergology and its impact in specific allergy diagnosis and therapy.
    Barber D; Diaz-Perales A; Escribese MM; Kleine-Tebbe J; Matricardi PM; Ollert M; Santos AF; Sastre J
    Allergy; 2021 Dec; 76(12):3642-3658. PubMed ID: 34057744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
    Wilcock LK; Francis JN; Durham SR
    Immunol Allergy Clin North Am; 2006 May; 26(2):333-47, viii-ix. PubMed ID: 16701148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.